Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck & Co. agreed to buy UK biotech Verona Pharma Plc for about $10 billion to offset the looming loss of patent protection ...

Merck & Co. is closing in on an approximately $10 billion deal to acquire respiratory drugmaker Verona Pharma, the Financial ...

Vicenza is a middle sized city in the Veneto region of Italy. Easily accessed from Venice, Padua, Verona, and many other ...

Advanced assistance technologies, if made available and sustainable, can represent a turning point for the quality of life of ...

Planning a winter vacation and wondering, does it snow in Italy? Here is your complete guide to when and where to experience ...